A phase 1, open-label, dose escalation study evaluating the safety and tolerability of EZN-2968, a locked nucleic acid antisense oligonucleotide against hypoxia-inducible factor-1alpha administered as a weekly 2-hour intravenous infusion in adult patients with advanced solid tumors or lymphoma

Trial Profile

A phase 1, open-label, dose escalation study evaluating the safety and tolerability of EZN-2968, a locked nucleic acid antisense oligonucleotide against hypoxia-inducible factor-1alpha administered as a weekly 2-hour intravenous infusion in adult patients with advanced solid tumors or lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2011

At a glance

  • Drugs RG 6061 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 02 Jun 2009 Interim results were presented at the American Society of Clinical Oncology (ASCO) meeting 2009, according to and Enzon Pharmaceuticals media release.
    • 24 Oct 2008 Status changed from recruiting to completed based on results reported at EORTC-NCI-AACR 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top